Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 14Lymphoid 14Tumor-Agnostic 8Thoracic 3Dermatologic 3Other hematologic neoplasm 2Sarcoma 1Plasma cell 1Other neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 3Neoplasms 2

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Rifampin × Dermatologic × Clear all
NCT02608034 2020-02-12

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Genentech, Inc.

Phase 1 Completed
32 enrolled
Dermatologic

Melanoma

NCT01954043 2017-11-14

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

GlaxoSmithKline

Phase 1 Completed
23 enrolled
Dermatologic

Melanoma, Neoplasms

NCT01765543 2016-12-15

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Hoffmann-La Roche

Phase 1 Completed
27 enrolled 16 charts
Dermatologic

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡